MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Invasive aspergillosis is a type of fungal infection typically identified in very sick
patients (for example, patients with cancer or who have had a bone marrow or organ
transplant). This study will seek to enroll patients (16 years of age or older) with invasive
aspergillosis infections (involving organs or deep tissues) who are failing or could not
tolerate standard antifungal therapy. Your doctor will make this determination based upon
specific study criteria. Patients that fulfill all study criteria will be treated daily with
both the investigational drug and another antifungal agent. The choice of the other agent is
up to your doctor. This investigational drug is approved for the treatment of invasive
aspergillosis by itself. The safety and efficacy of this investigational drug, in combination
with other agents is not known.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Amphotericin B Caspofungin Liposomal amphotericin B